| Authors: |
de Gruil N; Leiden University Medical Center, Leiden, The Netherlands., de Groot AF; Leiden University Medical Center, Leiden, The Netherlands., Wesseling-Rozendaal Y; InnoSIGN B.V., Eindhoven, The Netherlands., Keizer D; InnoSIGN B.V., Eindhoven, The Netherlands., Koekenbier CS; Leiden University Medical Center, Leiden, The Netherlands., Vermeer S; InnoSIGN B.V., Eindhoven, The Netherlands., Cohen D; Leiden University Medical Center, Leiden, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Mandigers CMPW; Department of Medical Oncology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands., van de Wouw AJ; Department of Medical Oncology, VieCuri Medical Center, Venlo, The Netherlands., Cloos-van Balen M; Department of Medical Oncology, Groene Hart Hospital, Gouda, The Netherlands., Ropela JA; Department of Medical Oncology, St. Jansdal, Harderwijk, The Netherlands., Oosterkamp HM; Department of Medical Oncology, Haaglanden Medical Center, The Hague, The Netherlands., van Bekkum ML; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, The Netherlands., Houtsma D; Department of Medical Oncology, HAGA Hospital, The Hague, The Netherlands., Biezen ED; InnoSIGN B.V., Eindhoven, The Netherlands., Liefers GJ; Leiden University Medical Center, Leiden, The Netherlands., Linn SC; Antoni van Leeuwenhoek Hospital, Amsterdam, and University Medical Center Utrecht, Utrecht, The Netherlands., Kroep JR; Leiden University Medical Center, Leiden, The Netherlands. j.r.kroep@lumc.nl. |
